Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70

Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.

Trial Locations (3)

Unknown

ACTIVE_NOT_RECRUITING

Radboud University Medical Centre, Nijmegen

RECRUITING

University Medical Centre Utrecht, Utrecht

ACTIVE_NOT_RECRUITING

Utrecht University, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

collaborator

Utrecht University

OTHER

collaborator

Trajectum Pharma B.V.

UNKNOWN

collaborator

Dutch Arthritis Association

INDUSTRY

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Health Holland

OTHER

lead

UMC Utrecht

OTHER

NCT05251870 - Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter